We use cookies to ensure that we give you the best experience on our website Learn more

Home

Saved research

Submission

New approaches in peripheral venous catheterization: JLB®, a new catheter for large veins

Submitted

19 Views
0 Downloads
0 Saves

Presented at

Euroanaesthesia 2017

-

Presentation

thumbnail

Abstract

Background: Patients with difficult intravenous access represent a contextual problem of emergency medicine setting. The spreading of ultrasound and the increasing fragility of the in-hospital population led to find new approaches of peripheral venous catheterization, trying to avoid invasive, expensive, time-consuming and prone to serious adverse events procedure, such as central venous catheterization. JLB® (Deltamed Inc) is an over the needle catheter designed for large peripheral veins, such as Internal Jugular vein (IJV). Its hyperecoic tip enables to perform easily an eco-guided bedside non-sterile (aseptic) technique. Materials and Methods: JLB® was distributed to 3 Emergency Medicine wards, 2 Anesthesiology and 1 Internal Medicine ward. A retrospective observational multicentric study was conducted from July 2015 to April 2016. The device was inserted using a high frequency linear probe. Data have been collected referring to demographics, device specifications (available in 80/70/60 mm length,14/16/17/18 Gauge diameter), procedure times and complications. Results: Preliminary data refer to 214 cases of 400 enrolled. Mean age 72.9 years ± 16, SD; 121 women. Main indication for cannulation with JLB® were peripheral venous pool depletion and need of inotropes. Positioning site: IJV (90,6%), Basilic/Cephalic (8,9%). No major adverse events (iatrogenic pneumothorax, arterial cannulation, thrombosis, major arrhythmia and devices related infection); 3 minor complications (soft tissues haematoma, atrial fibrillation, self-removal); Indications to removal: no more requirement and death. Mean procedure time: <4min. Success at first attempt of cannulation: 77.5%. Conclusion: Actually JLB® results safe and improves patient management and costs, especially when alternative techniques could be an overtreatment.

Datasets

No datasets are available for this submission.

License

No license information is available for this submission.

Morressier

Company

Legal

Follow us

© Copyright 2020 Morressier GmbH. All rights reserved.

Morressier

© Copyright 2020 Morressier GmbH.
All rights reserved.